相关实验视频
Updated: Jun 22, 2025

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.8K
对支持替代第一线疗法而不是二甲双在2型糖尿病中的替代第一线疗法的数据进行叙述性审查
John Andraos1, Shawn R Smith1, Amanda Tran2
1Western University of Health Sciences, College of Pharmacy, Pomona, CA USA.
Journal of diabetes and metabolic disorders
|June 27, 2024
概括
较新的糖尿病药物,葡萄糖类-1受体激动剂 (GLP-1 RA) 和-葡萄糖共传输体-2抑制剂 (SGLT-2i),显示出独立于甲胺的好处. 这些药物可以为特定患者提供有效的第一线治疗.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 甲胺一直是2型糖尿病的标准第一线治疗方法,因为其已被证明的疗效,安全性和成本效益.
- 最近的进展突出显示了葡萄糖类-1受体激动剂 (GLP-1 RA) 和-葡萄糖共传输体-2抑制剂 (SGLT-2i) 的心脏保护和保护作用.
- 这些新出现的好处促使人们重新评估糖尿病管理中的一线治疗指南.
研究的目的:
- 审查梅特福林在2型糖尿病治疗中的一线状态的历史基础.
- 评估GLP-1RA和SGLT-2的益处是否在作为单疗法使用时保持,独立于甲胺.
- 为了比较较新的药物与甲福明的疗效,当它们被用作独立治疗时.
主要方法:
- 使用PubMed.com进行了全面的文献搜索.
- 审查了最近的糖尿病管理指南中的引用.
- 审查的重点是支持甲胺的历史数据和评估新药与甲胺或不含甲胺的研究.
主要成果:
- 历史文献证实了梅特福林作为一线药剂的既定作用.
- GLP-1 RAs和SGLT-2is的治疗益处独立于同时使用甲福林.
- 与较新的药物单一治疗在各种研究中表明,与单独使用甲福明相比,结果不逊色或优越.
结论:
- GLP-1 RAs和SGLT-2is是针对特定患者群体的可行的第一线单一疗法,特别是那些心血管风险高,脏疾病或体重管理需要的人.
- 药物经济因素和长期安全数据要求对这些新药的使用进行仔细考虑.
- 糖尿病管理的不断变化的格局强调了患者和临床医生之间的共同决策.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Carbohydrate Metabolism
11.0K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.0K
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
169
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
169

